Regenxbio Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance

More Details of Regenxbio Inc Company

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

Regenxbio Inc Info



Ticker SymbolRGNX

Company nameRegenxbio Inc

IPO dateSep 17, 2015

CEOMr. Curran M. Simpson

Number of employees353

Security typeOrdinary Share

Fiscal year-endSep 17

Address9804 Medical Center Drive

CityROCKVILLE

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code20850

Phone12405528181

Websitehttps://regenxbio.com/

Ticker SymbolRGNX

IPO dateSep 17, 2015

CEOMr. Curran M. Simpson

Company Executives of Regenxbio Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

53.97K

-8.33%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.59K

-1.31%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

16.11K

-48.81%

Mr. Allan M. Fox, J.D.

Director

--

Dr. David C. (Dave) Stump, M.D.

Independent Director

--

Dr. A. N. (Jerry) Karabelas, Ph.D.

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

53.97K

-8.33%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.59K

-1.31%

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Sat, Nov 8

Shareholders

Shareholder Types

Shareholders

Proportion

Redmile Group, LLC

9.43%

BlackRock Institutional Trust Company, N.A.

8.43%

The Vanguard Group, Inc.

6.59%

Fox (Allan Mark)

5.73%

JP Morgan Asset Management

5.16%

Other

64.66%

Shareholders

Proportion

Redmile Group, LLC

9.43%

BlackRock Institutional Trust Company, N.A.

8.43%

The Vanguard Group, Inc.

6.59%

Fox (Allan Mark)

5.73%

JP Morgan Asset Management

5.16%

Other

64.66%

Shareholder Types

Shareholders

Proportion

Investment Advisor/Hedge Fund

33.94%

Investment Advisor

31.21%

Hedge Fund

12.74%

Individual Investor

7.62%

Research Firm

6.92%

Pension Fund

0.28%

Bank and Trust

0.26%

Family Office

0.26%

Private Equity

0.06%

Other

6.73%

Institutional Shareholding



Updated: Wed, Oct 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q3

403

44.05M

87.32%

-5.71M

2025Q2

421

48.19M

95.62%

-3.63M

2025Q1

446

48.46M

96.35%

-3.90M

2024Q4

444

48.16M

97.22%

-4.82M

2024Q3

444

49.64M

100.43%

-4.45M

2024Q2

437

49.30M

99.98%

-3.20M

2024Q1

451

48.23M

99.21%

+414.63K

2023Q4

436

43.62M

98.84%

-7.14M

2023Q3

439

43.73M

99.56%

-6.26M

2023Q2

439

43.86M

100.57%

-5.31M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Redmile Group, LLC

4.78M

9.45%

-19.06K

-0.40%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.27M

8.45%

+348.80K

+8.90%

Jun 30, 2025

The Vanguard Group, Inc.

3.42M

6.77%

-51.80K

-1.49%

Jun 30, 2025

Fox (Allan Mark)

2.90M

5.74%

+7.77K

+0.27%

May 30, 2025

JP Morgan Asset Management

2.99M

5.91%

+38.82K

+1.32%

Jun 30, 2025

State Street Investment Management (US)

1.84M

3.65%

+777.55K

+72.93%

Jun 30, 2025

BlackRock Financial Management, Inc.

1.73M

3.43%

+637.97K

+58.36%

Jun 30, 2025

Goldman Sachs & Company, Inc.

1.61M

3.18%

+962.62K

+149.64%

Jun 30, 2025

Geode Capital Management, L.L.C.

1.13M

2.23%

+21.57K

+1.95%

Jun 30, 2025

Dimensional Fund Advisors, L.P.

1.12M

2.22%

-24.96K

-2.17%

Jun 30, 2025

Related ETFs



Updated: Thu, Nov 6

Name

Proportion

WisdomTree BioRevolution Fund

1.92%

iShares Neuroscience and Healthcare ETF

0.79%

Virtus LifeSci Biotech Clinical Trials ETF

0.68%

Global X Genomics & Biotechnology ETF

0.51%

JPMorgan Fundamental Data Science Small Core ETF

0.32%

ALPS Medical Breakthroughs ETF

0.29%

SPDR S&P Biotech ETF

0.16%

Direxion Daily S&P Biotech Bull 3X Shares

0.09%

iShares Health Innovation Active ETF

0.09%

Fidelity Enhanced Small Cap ETF

0.08%

WisdomTree BioRevolution Fund

Proportion1.92%

iShares Neuroscience and Healthcare ETF

Proportion0.79%

Virtus LifeSci Biotech Clinical Trials ETF

Proportion0.68%

Global X Genomics & Biotechnology ETF

Proportion0.51%

JPMorgan Fundamental Data Science Small Core ETF

Proportion0.32%

ALPS Medical Breakthroughs ETF

Proportion0.29%

SPDR S&P Biotech ETF

Proportion0.16%

Direxion Daily S&P Biotech Bull 3X Shares

Proportion0.09%

iShares Health Innovation Active ETF

Proportion0.09%

Fidelity Enhanced Small Cap ETF

Proportion0.08%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split



Date

Type

Ratio

No Data

Date

Type

Ratio

No Data